ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis
Links shared publicly online about this topic.
- 588total visits
ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
View full resource at news-medical.net
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Clinical Trial, Betaseron, Betaferon, Safety
Most Recently Shared on January 11, 2011 at 5:46 pm By:
ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis: ALLOZYNE, Inc. announ... http://bit.ly/enu7R9
ALLOZYNE Announces Completion Of Phase IA Trial By AZ01, A Long Lasting Interferon For Treatment Of Relapsing Remitting Multiple Sclerosis
medicalnewstoday.com — “ALLOZYNE, Inc. announced, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatme” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 2:05 pm By:
ALLOZYNE Announces Completion Of Phase IA Trial By AZ01, A Long Lasting Interferon ? For Treatment Of Relapsing Remit... http://mnt.to/3PWJ
Advertisement
